NEW YORK, November 22, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Elan Corporation, plc (NYSE: ELN), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Hospira Inc. (NYSE: HSP), and Alkermes plc (NASDAQ: ALKS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Elan Corporation, plc Research Report
On November 18, 2013, Elan Corporation, plc (Elan) announced that the Company's shareholders have approved the acquisition of Elan by Perrigo Company at two special meetings: a special court-ordered meeting, and an extraordinary general meeting. According to Elan, both Companies have entered into a definitive agreement pursuant to which a new holding company incorporated in Ireland will acquire the Company in a stock-and-cash transaction. The Full Research Report on Elan Corporation, plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/e996_ELN
IntelliPharmaCeutics International Inc. Research Report
On November 18, 2013, IntelliPharmaCeutics International Inc. (IntelliPharmaCeutics) announced that the US Food and Drug Administration (FDA) has granted final approval of the Company's dexmethylphenidate hydrochloride extended-release capsules for the 15 mg and 30 mg strengths. According to the Company, the commercial sale of the said capsules will be launched immediately by Par Pharmaceuticals, Inc. (Par Pharmaceuticals), the Company's commercialization partner in the US. Dr. Isa Odidi, CEO and Co-Founder of IntelliPharmaCeutics stated, "FDA approval of our application for a generic version of Focalin XR® is a major milestone for the Company in several respects. We believe that the approval represents a strong validation of our core drug development competence and our controlled-release delivery technologies. At the same time, we have demonstrated that we can partner with an established and well-regarded pharmaceutical company, in this case Par Pharmaceutical, to see a product through to commercialization in the United States." The Full Research Report on IntelliPharmaCeutics International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/00e6_IPCI
Valeant Pharmaceuticals International, Inc. Research Report
On November 15, 2013, Valeant Pharmaceuticals International, Inc. (Valeant Pharmaceuticals) announced that it has priced its previously announced offering of 5.625% senior unsecured notes due 2021. According to the Company, it has increased the offering to $900 million from the previous $850 million aggregate principal amount of the Notes. The Company also stated that the new proceeds of the offering is to be used to finance the redemption of all of the Company's wholly-owned subsidiary's 6.50% Senior Notes due 2016, as well as to pay fees and expenses related to the foregoing. Additionally, Valeant Pharmaceuticals stated that it has irrevocably called for redemption $450 million aggregate principal amount of its 6.50% Senior Notes due 2016, and that upon the closing date of the offering, it intends to irrevocably call for redemption the remaining $465.5 million aggregate principal amount of its 6.50% Senior Notes due 2016 and use the remaining net proceeds from this offering to pay the redemption price of the notes called. The offering is expected to close on December 2, 2013. The Full Research Report on Valeant Pharmaceuticals International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/9fdd_VRX
Hospira Inc. Research Report
On November 19, 2013, Hospira Inc.'s (Hospira) stock declined by 1.05%, ending the day with $38.59 per share. Over the past three trading days, the Company's stock went down by 2.13%, compared to the Dow Jones Industrial Average which went up by 0.57% during the same period. The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/1f43_HSP
Alkermes plc Research Report
On November 19, 2013, Alkermes plc's (Alkermes) stock was up by 1.22%, closing at $37.34 per share. Over the three trading day period, the Company's stock declined by 0.16%, compared to the Nasdaq Composite which went down by 1.04% during the same period. The Full Research Report on Alkermes plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/e2f3_ALKS
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.analystscorner.com/
SOURCE Analysts' Corner
